Additional Analyses Results, Stock Price Updates, Products & Services Deployment, and Proposed Public Offerings - Research Report on CytRx, Intrexon, Allscripts, Acceleron, and NewLink Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, January 15, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting CytRx Corporation (NASDAQ: CYTR), Intrexon Corporation (NYSE: XON), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Acceleron Pharma, Inc. (NASDAQ: XLRN), and NewLink Genetics Corporation (NASDAQ: NLNK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
CytRx Corporation Research Report
On January 8, 2014, CytRx Corporation (CytRx) reported positive results from additional statistical analyses that further support the previously reported strong top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx's President and CEO, Steven A. Kriegsman, said, "Because of the tremendous potential for aldoxorubicin to treat soft tissue sarcomas and other common cancers, it is important that we present the initial trial analyses in a timely manner. We are very pleased that additional statistical analyses strongly support the earlier top-line results, which reinforces our confidence in the ability of our linker technology to target the release of doxorubicin directly at the site of cancer." The Full Research Report on CytRx Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Intrexon Corporation Research Report
On January 10, 2014, Intrexon Corporation's (Intrexon) stock increased 10.67%, ending the day's trading session at $29.87. Over the previous three trading sessions, shares of Intrexon increased 26.03%, compared to the Dow Jones Industrial Average Index which declined 0.57% during the same period. The Full Research Report on Intrexon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Allscripts Healthcare Solutions, Inc. Research Report
On January 9, 2014, Allscripts Healthcare Solutions, Inc. (Allscripts) reported that Dameron Hospital Association, a full-service hospital in Stockton, California, has selected the Company's Sunrise™ clinical product suite as its electronic health record (EHR) solution, deploying key products and services to optimize care coordination, patient engagement and patient outcomes. Lorraine Auerbach, Dameron Hospital's President and CEO, said, "Allscripts Sunrise has a range of capabilities that make it the perfect solution for Dameron. Allscripts Sunrise's care coordination, integration and population health capabilities will help us continue to provide the best possible care for our community well into the future." Paul M. Black, President and CEO of Allscripts, added, "Dameron has a legacy of care within the community of Stockton. We are delighted to be their partner, and deliver a suite of solutions that will help them deliver exceptional outcomes and provide high-quality and cost-efficient care." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Acceleron Pharma, Inc. Research Report
On January 9, 2014, Acceleron Pharma, Inc. (Acceleron) reported that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding the proposed underwritten public offering of its common stock. According to the Company, all shares of common stock to be sold in the offering will be offered by Acceleron. The Company informed that Citigroup and Leerink Partners LLC will serve as joint book-running managers for the offering, while Piper Jaffray & Co. and JMP Securities will serve as lead manager and co-manager for the offering, respectively. The Full Research Report on Acceleron Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
NewLink Genetics Corporation Research Report
On January 10, 2014, NewLink Genetics Corporation's (NewLink) stock increased 6.34%, ending the day's trading session at $24.84. Over the previous three trading sessions, shares of NewLink increased 8.71%, compared to the Nasdaq Composite Index which increased 0.52% during the same period. The Full Research Report on NewLink Genetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner